Table 1.
Cardiovascular baselines prior to 3,4-DAP, i.e., after pre-treatment, and the response to pre-treatment below in parenthesis.
Pre-treatment | WKY |
SHR |
|||||
---|---|---|---|---|---|---|---|
MBP (mm Hg) | HR (bpm) | TPR (mm Hg/ml/min) | MBP (mm Hg) | HR (bpm) | TPR (mm Hg/ml/min) | ||
PBS | Vehicle | 65 ± 5 (1 ± 1) |
301 ± 15 (−7 ± 5) |
2.10.1 (−0.1 ± 0.0) |
84 ± 6* (−5 ± 4) |
381 ± 12* (−8 ± 9) |
5.2 ± 0.6* (−0.7 ± 0.2) |
Hemicholinium-3 | Ach synthesis inhibitor | 58 ± 4 (−26 ± 4)† |
303 ± 16 (−5 ± 8) |
2.1 ± 0.1 (−0.5 ± 0.1)† |
60 ± 7 (−21 ± 7) |
354 ± 14 (−43 ± 9)† |
3.1 ± 0.2† (−0.9 ± 0.3) |
Hexamethonium | nAchR antagonist | 39 ± 5† (−29 ± 6)† |
257 ± 12 (−53 ± 14)† |
1.7 ± 0.1 (−0.7 ± 0.2)† |
53 ± 2† (−33 ± 7)† |
345 ± 19 (−67 ± 8)† |
2.9 ± 0.2† (−1.5 ± 0.2)† |
Atropine | mAchR antagonist | 68 ± 10 (−2 ± 3) |
307 ± 15 (19 ± 12) |
1.7 ± 0.2 (−0.3 ± 0.1) |
76 ± 4 (5 ± 7) |
374 ± 13 (−33 ± 6) |
3.9 ± 0.3 (−0.1 ± 0.2) |
Reserpinea + PBS | Depletes norepinephrine | 58 ± 3 (0 ± 0) |
307 ± 4 (−14 ± 4) |
2.0 ± 0.1 (0.0 ± 0.0) |
62 ± 4 (1 ± 2) |
309 ± 12† (−23 ± 5) |
4.1 ± 0.3 (0.4 ± 0.1)† |
Reserpine + atropine | 66 ± 4 (−7 ± 2)† |
328 ± 9 (5 ± 12) |
1.9 ± 0.1 (−0.3 ± 0.1) |
73 ± 6 (1 ± 2) |
278 ± 8† (−19 ± 11) |
4.3 ± 0.4 (−0.4 ± 0.3) |
|
Nadolol | β1+2AR antagonist | 61 ± 4 (2 ± 1) |
312 ± 6 (−10 ± 2) |
2.0 ± 0.2 (0.0 ± 0.1) |
69 ± 5 (−8 ± 3) |
343 ± 6 (−67 ± 25)† |
3.9 ± 0.3 (−0.1 ± 0.2) |
Atropine + nadolol | Not done | 61 ± 9 (−9 ± 4) |
325 ± 12 (−33 ± 6) |
3.8 ± 0.2 (−0.0 ± 0.2) |
|||
Quinidine | Antiarrhythmic + KV/KAch inhibitor | Not done | 67 ± 5 (−42 ± 9)† |
313 ± 14 (−63 ± 13)† |
2.5 ± 0.4† (−1.2 ± 0.4) |
aSince reserpine was administered prior to the experiment, the effect of reserpine is indicated by the differences in baselines. Comparisons were made between the WKY and SHR controls (*) and between the PBS control and experimental groups within each strain (†). Sixteen rats were included in the WKY and SHR controls, and 6–9 rats in the experimental groups.
*P ≤ 0.017.
†P ≤ 0.006.